San Diego, CA -- (SBWIRE) -- 08/11/2014 -- An investigation on behalf of investors of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares over potential securities laws violations by Regeneron Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced .

Investors who purchased shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Regeneron Pharmaceuticals Inc concerning whether a series of statements by Regeneron Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Regeneron Pharmaceuticals Inc reported that its annual Total Revenue rose from $445.82 million in 2011 to over $2.1 billion in 2013 and its Net Loss of $221.76 million in 2011 turned into a net Income of $424.36 million in 2013. Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) grew from $34.10 per share in early 2011 to as high as $347.62 per share in February 2014.

On August 8, 2014, NASDAQ:REGN shares closed at $338.32 per share.

Those who purchased shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com